- Home
- AEAQ vs PROK Comparison
AEAQ vs PROK Comparison
Compare AEAQ & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AEAQ | PROK |
|---|---|---|
| Founded | 2025 | 2015 |
| Country | Cayman Islands | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 310.3M | 331.2M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEAQ | PROK |
|---|---|---|
| Price | $9.90 | $2.09 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.40 |
| AVG Volume (30 Days) | 66.2K | ★ 508.7K |
| Earning Date | 01-01-0001 | 03-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $893,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $25.00 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1075.00 |
| 52 Week Low | $9.88 | $0.46 |
| 52 Week High | $9.94 | $7.13 |
Technical Indicators
Market Signals| Indicator | AEAQ | PROK |
|---|---|---|
| Relative Strength Index (RSI) | 50.82 | 42.95 |
| Support Level | N/A | $1.71 |
| Resistance Level | $9.94 | $2.58 |
| Average True Range (ATR) | 0.01 | 0.16 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 33.33 | 5.71 |
Price Performance
Historical ComparisonAbout AEAQ Activate Energy Acquisition Corp. Class A Ordinary Share
Activate Energy Acquisition Corp is a blank check company formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.